Clinical Trial Update: PCSK9 Inhibitor Treatment for Patients With SPG5 [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for a PCSK9 inhibitor in patients with Hereditary Spastic Paraplegia Type 5 (Phase 1/2).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Spastic Paraplegia Type 5

Drugs mentioned

• PCSK9 inhibitor (PCSK9 inhibitor)

Snippet

Sponsor: First Affiliated Hospital of Fujian Medical University | Conditions: Hereditary Spastic Paraplegia Type 5 | Phase 1, Phase 2 | Status: UNKNOWN